contains medroxyprogesterone acetate & estradiol cypionate; contains 25 mg medroxyprogesterone acetate and 5 mg estradiol-cypionate
Also Known As:
Cyclofem; HRP 112; HRP112
Networked: 19 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Simbar, Masoumeh: 2 articles (04/2015 - 10/2007)
2. Sheikhan, Zohre: 1 article (04/2015)
3. Ozgoli, Giti: 1 article (04/2015)
4. Nasiri, Malihe: 1 article (04/2015)
5. Bakhtyari, Maryam: 1 article (04/2015)
6. Dolatian, Mahrokh: 1 article (04/2015)
7. Zangeneh, Maryam: 1 article (09/2013)
8. Veisi, Firoozeh: 1 article (09/2013)
9. Fraser, Ian S: 1 article (10/2007)
10. Tehrani, Fahimeh Ramezani: 1 article (10/2007)

Related Diseases

1. Amenorrhea
2. Hemorrhage
3. Metrorrhagia (Spotting)
4. Hypertension (High Blood Pressure)
5. Dysmenorrhea (Menstrual Pain)
01/01/1998 - "The most frequently cited problems among Cyclofem users included breast tenderness, abdominal pain, and dysmenorrhea; yet a third of these women opted to stay on Cyclofem at the end of the study. "
01/01/1998 - " Although 94% of Cyclofem users compared with only 22% of DMPA users experienced minor side effects (breast tenderness, abdominal pain, dysmenorrhea) during the 6-month study period, 34% of these women elected to remain on Cyclofem at the end of the study. "
01/01/1995 - " Contraception for women comprises the following: 1) agents that prevent ovulation; prolonged breast feeding (98% safe contraception within the first 6 months); oral contraceptives containing estrogens and gestagens (60-80 million women use them worldwide; in 1968 the 50 g estrogen containing pill, in 1972 the micropill with 30 g of ethinyl estradiol [EE], and in 1992 the ultra-low-dose pill with 20 g of EE were introduced); and future developments (third generation progestagens, antigestagens, nonsteroidal natural substances, melatonin, the combination of gonadotropin-releasing hormone analogs and natural estrogens); 2) prevention of fertilization: mechanical methods (diaphragm, sterilization methods by laparoscopy or chemical means); chemical methods (spermicides such as nonoxynol); behavioral methods (temperature methods using refined measurement of the body temperature, cervical mucus resistance); hormonal methods (implants such as Norplant containing levonorgestrel [LNG], Implanon containing 3-ketodesogestrel, the vaginal ring [the WHO-ring and the Organon ring], the minipill with pure gestagen, one-month injection with Cyclofem), IUDs (copper-containing IUDs, LNG-containing IUDs with a Pearl Index of 0.2-0.5 and reduction of dysmenorrhea); and immunological contraception (ovum and spermatozoon antigens); 3) the prevention of implantation: hormonal methods (the morning-after pill with high-dose EE or the combination of estrogen and gestagen); insertion of an IUD up to the 6th day after coitus; immunological methods (human chorionic gonadotropin antibodies, antibodies against the zona pellucida glycoproteins, implantation inhibition through interaction with interleukin IL-1 receptor, and antibodies against specific proteins of the endometrium influencing implantation). "

Related Drugs and Biologics

1. N,N-dimethyl-4-anisidine (DMPA)
2. norethindrone drug combination estradiol
3. estradiol 17 beta-cypionate (Depo-estradiol)
4. Medroxyprogesterone Acetate (Depo-Provera)
5. Estrogens (Estrogen)
6. HDL Cholesterol
7. Injectable No. 1
8. 17-alpha-Hydroxyprogesterone (17 Hydroxyprogesterone)
9. Nonoxynol (Nonoxynol 9)
10. Levonorgestrel (Plan B)

Related Therapies and Procedures

1. Injections
2. Contraception (Birth Control)
3. Female Contraceptive Devices (Vaginal Ring)
4. Immunologic Contraception (Immunocontraception)